Galanin receptors as a potential target for neurological disease

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 12, 2015, Pages 1665-1676

  Freimann, Krista ^a   Kurrikoff, Kaido ^a   Langel, Ülo ^a,b  

^a UNIVERSITY OF TARTU   (Estonia)

^b STOCKHOLM UNIVERSITY   (Sweden)

Author keywords

Alzheimer's disease; depression; epilepsy; galanin; galanin receptors; ligands; neurological disease; neuropeptide

Indexed keywords

1 PHENYL 3 [[3 (TRIFLUOROMETHYL)PHENYL]IMINO] 1H INDOL 2 ONE; 1 [3 [2 (PYRROLIDIN 1 YL)ETHOXY]PHENYL] 3 [3 (TRIFLUOROMETHYL)PHENYLIMINO] INDOLIN 2 ONE; 2,3 DIHYDRO 2 (4 METHYLPHENYL) 1,4 DITHIEPINE 1,1,4,4 TETROXIDE; 7 [(9 FLUORENYLMETHOXYCARBONYL)CYCLOHEXYLALANYLLYSYL] AMINO 4 METHYLCOUMARIN; GAL (1-16) PEPTIDE; GAL (2-29) PEPTIDE; GAL (3-29) PEPTIDE; GAL B2 PEPTIDE; GALANIN; GALANIN DERIVATIVE; GALANIN RECEPTOR; GALANIN RECEPTOR 2; GALANIN RECEPTOR 3; HGAL (1-30) PEPTIDE; J18 PEPTIDE; M15 PEPTIDE; M35 PEPTIDE; M40 PEPTIDE; M617 PEPTIDE; M871 PEPTIDE; SPIROCOUMARANONE; UNCLASSIFIED DRUG; LIGAND;

ALZHEIMER DISEASE; BINDING AFFINITY; BRAIN REGION; CENTRAL NERVOUS SYSTEM; DEPRESSION; DRUG DEVELOPMENT; EPILEPSY; HIPPOCAMPUS; HUMAN; IC50; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; NEUROCHEMISTRY; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; REVIEW; SEIZURE; ANIMAL; DRUG DESIGN; METABOLISM; MOLECULARLY TARGETED THERAPY; NERVOUS SYSTEM DISEASES; PATHOPHYSIOLOGY;

ANIMALS; DRUG DESIGN; GALANIN; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; NERVOUS SYSTEM DISEASES; RECEPTORS, GALANIN;

EID: 84952872710     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1072513     Document Type: Review

References (152)

1. Tatemoto K, Rökaeus Å, Jörnvall H, et al. Galanin - a novel biologically active peptide from porcine intestine. FEBS Lett 1983;164(1):124-8
2. Vrontakis ME, Peden LM, Duckworth ML, Friesen HG. Isolation and characterization of a complementary DNA (galanin) clone from estrogeninduced pituitary tumor messenger RNA. J Biol Chem 1987;262(35):16755-8
3. Hökfelt T, Tatemoto K. Galanin: a multitalented neuropeptide. In: Hökfelt T, editor. Galanin [Internet]. Springer Basel; 2010. p. 1-5. Available from: http://dx. doi.org/10.1007/978-3-0346-0228-0-1
4. Lundkvist J, Land T, Kahl U, et al. cDNA sequence, ligand biding, and regulation of galanin/GMAP in mouse brain. Neurosci Lett 1995;200(2):121-4
5. Santic R, Fenninger K, Graf K, et al. Gangliocytes in neuroblastic tumors express alarin, a novel peptide derived by differential splicing of the galanin-like peptide gene. J Mol Neurosci 2006;29(2):145-52
6. Ohtaki T, Kumano S, Ishibashi Y, et al. Isolation and cDNA cloning of a novel galanin-like peptide (GALP) from porcine hypothalamus. J Biol Chem 1999;274(52):37041-5
7. Webling KEB, Runesson J, Bartfai T, Langel Ü. Galanin Receptors and Ligands. Front Endocrinol 2012;3:146
8. Garcia-Falgueras A, Ligtenberg L, Kruijver FPM, Swaab DF. Galanin neurons in the intermediate nucleus (InM) of the human hypothalamus in relation to sex, age, and gender identity. J Comp Neurol 2011;519(15):3061-84
9. Gentleman SM, Falkai P, Bogerts B, et al. Distribution of galanin-like immunoreactivity in the human brain. Brain Res 1989;505(2):311-15
10. Lein ES, Hawrylycz MJ, Ao N, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 2007;445(7124):168-76
11. Cheung CC, Hohmann JG, Clifton DK, Steiner RA. Distribution of galanin messenger RNA-expressing cells in murine brain and their regulation by leptin in regions of the hypothalamus. Neuroscience 2001;103(2):423-32
12. Pérez SE, Wynick D, Steiner RA, Mufson EJ. Distribution of galaninergic immunoreactivity in the brain of the mouse. J Comp Neurol 2001;434(2):158-85
13. Ryan MC, Gundlach AL. Localization of preprogalanin messenger RNA in rat brain: identification of transcripts in a subpopulation of cerebellar Purkinje cells. Neuroscience 1996;70(3):709-28
14. Skofitsch G, Jacobowitz DM. Immunohistochemical mapping of galanin-like neurons in the rat central nervous system. Peptides 1985;6(3):509-46
15. Kinney JW, Starosta G, Holmes A, et al. Deficits in trace cued fear conditioning in galanin-treated rats and galanin-overexpressing transgenic mice. Learn Mem Cold Spring Harb N 2002;9(4):178-90
16. McDonald MP, Gleason TC, Robinson JK, Crawley JN. Galanin inhibits performance on rodent memory tasks. Ann N Y Acad Sci 1998;863:305-22
17. Liu H, Hökfelt T. Effect of intrathecal galanin and its putative antagonist M35 on pain behavior in a neuropathic pain model. Brain Res 2000;886(1-2):67-72
18. Gundlach AL. Galanin/GALP and galanin receptors: role in central control of feeding, body weight/obesity and reproduction? Eur J Pharmacol 2002;440(2-3):255-68
19. Landry M, Roche D, Vila-Porcile E, Calas A. Effects of centrally administered galanin (1-16) on galanin expression in the rat hypothalamus. Peptides 2000;21(11):1725-33
20. Crawley JN. The role of galanin in feeding behavior. Neuropeptides 1999;33(5):369-75
21. Wiesenfeld-Hallin Z, Xu X-J, Crawley JN, Hökfelt T. Galanin and spinal nociceptive mechanisms: Recent results from transgenic and knock-out models. Neuropeptides 2005;39(3):207-10
22. Kyrkouli SE, Glenn Stanley B, Leibowitz SF. Galanin: Stimulation of feeding induced by medial hypothalamic injection of this novel peptide. Eur J Pharmacol 1986;122(1):159-60
23. Kuteeva E, Hökfelt T, Wardi T, Ögren SO. Galanin, Galanin Receptor Subtypes and Depression-Like Behaviour. In: Hökfelt T, editor. Galanin [Internet]. Springer Basel; 2010. p. 163-81. Available from: http://link.springer.com/chapter/10.1007/978-3-0346-0228-0-12 [Last accessed 18 April 2015]
24. Kuteeva E, Wardi T, Hökfelt T, Ögren SO. Galanin enhances and a galanin antagonist attenuates depressionlike behaviour in the rat. Eur Neuropsychopharmacol 2007;17(1):64-9
25. Zhang X, Nicholas AP, Hökfelt T. Ultrastructural studies on peptides in the dorsal horn of the spinal cord-I. Coexistence of galanin with other peptides in primary afferents in normal rats. Neuroscience 1993;57(2):365-84
26. Merchenthaler I, Lopez FJ, Negro-Vilar A. Colocalization of galanin and luteinizing hormone-releasing hormone in a subset of preoptic hypothalamic neurons: anatomical and functional correlates. Proc Natl Acad Sci USA 1990;87(16):6326-30
27. Miller MA, Kolb PE, Planas B, Raskind MA. Few cholinergic neurons in the rat basal forebrain coexpress galanin messenger RNA. J Comp Neurol 1998;391(2):248-58
28. Melander T, Hökfelt T, Rökaeus A, et al. Coexistence of galanin-like immunoreactivity with catecholamines, 5-hydroxytryptamine, GABA and neuropeptides in the rat CNS. J Neurosci Off J Soc Neurosci 1986;6(12):3640-54
29. Zhang X, Nicholas AP, Hökfelt T. Ultrastructural studies on peptides in the dorsal horn of the rat spinal cord-II. Coexistence of galanin with other peptides in local neurons. Neuroscience 1995;64(4):875-91
30. Kofler B, Evans HF, Liu ML, et al. Characterization of the 5′-flanking region of the human preprogalanin gene. DNA Cell Biol 1995;14(4):321-9
31. Rökaeus A, Brownstein MJ. Construction of a porcine adrenal medullary cDNA library and nucleotide sequence analysis of two clones encoding a galanin precursor. Proc Natl Acad Sci USA 1986;83(17):6287-91
32. Kofler B, Liu ML, Jacoby AS, et al. Molecular cloning and characterisation of the mouse preprogalanin gene. Gene 1996;182(1-2):71-5
33. Evans H, Baumgartner M, Shine J, Herzog H. Genomic organization and localization of the gene encoding human preprogalanin. Genomics 1993;18(3):473-7
34. Lang R, Gundlach AL, Holmes FE, et al. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol Rev 2015;67(1):118-75
35. Habu A, Ohishi T, Mihara S, et al. Isolation and sequence determination of galanin from the pituitary of yellow fin tuna. Biomed Res 1994;15(6):357-62
36. Land T, Langel U, Löw M, et al. Linear and cyclic N-terminal galanin fragments and analogs as ligands at the hypothalamic galanin receptor. Int J Pept Protein Res 1991;38(3):267-72
37. Kakuyama H, Kuwahara A, Mochizuki T, et al. Role of N-terminal active sites of galanin in neurally evoked circular muscle contractions in the guinea-pig ileum. Eur J Pharmacol 1997;329(1):85-91
38. Corness J, Stevens B, Fields RD, Hökfelt T. NGF and LIF both regulate galanin gene expression in primary DRG cultures. Neuroreport 1998;9(7):1533-6
39. Brann DW, Chorich LP, Mahesh VB. Effect of progesterone on galanin mRNA levels in the hypothalamus and the pituitary: correlation with the gonadotropin surge. Neuroendocrinology 1993;58(5):531-8
40. Hooi SC, Koenig JI, Abraczinskas DR, Kaplan LM. Regulation of anterior pituitary galanin gene expression by thyroid hormone. Brain Res Mol Brain Res 1997;51(1-2):15-22
41. Vrontakis ME, Yamamoto T, Schroedter IC, et al. Estrogen induction of galanin synthesis in the rat anterior pituitary gland demonstrated by in situ hybridization and immunohistochemistry. Neurosci Lett 1989;100(1-3):59-64
42. Mohney RP, Zigmond RE. Galanin expression is decreased by cAMPelevating agents in cultured sympathetic ganglia. Neuroreport 1999;10(6):1221-4
43. Lundström L, Elmquist A, Bartfai T, Langel U. Galanin and its receptors in neurological disorders. Neuromolecular Med 2005;7(1-2):157-80
44. Wraith DC, Pope R, Butzkueven H, et al. A role for galanin in human and experimental inflammatory demyelination. Proc Natl Acad Sci USA 2009;106(36):15466-71
45. Mazarati AM, Liu H, Soomets U, et al. Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. J Neurosci Off J Soc Neurosci 1998;18(23):10070-7
46. Mazarati AM, Halászi E, Telegdy G. Anticonvulsive effects of galanin administered into the central nervous system upon the picrotoxin-kindled seizure syndrome in rats. Brain Res 1992;589(1):164-6
47. Mazarati AM. Galanin and galanin receptors in epilepsy. Neuropeptides 2004;38(6):331-43
48. Ignatov A, Hermans-Borgmeyer I, Schaller HC. Cloning and characterization of a novel G-protein-coupled receptor with homology to galanin receptors. Neuropharmacology 2004;46(8):1114-20
49. Lang R, Gundlach AL, Kofler B. The galanin peptide family: Receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 2007;115(2):177-207
50. Liu Z, Xu Y, Wu L, Zhang S. Evolution of Galanin Receptor Genes: Insights from the Deuterostome Genomes. J Biomol Struct Dyn 2010;28(1):97-106
51. Lang R, Gundlach AL, Kofler B. The galanin peptide family: Receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol Ther 2007;115(2):177-207
52. Fuxe K, Jansson A, Diaz-Cabiale Z, et al. Galanin modulates 5-hydroxytryptamine functions. Focus on galanin and galanin fragment/5-hydroxytryptamine1A receptor interactions in the brain. Ann N Y Acad Sci 1998;863:274-90
53. Fuxe K, Marcellino D, Rivera A, et al. Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Basal Ganglia 2008;58(2):415-52
54. Fuxe K, Borroto-Escuela DO, Romero-Fernandez W, et al. On the existence and function of galanin receptor heteromers in the central nervous system. Front Endocrinol 2012;3:127
55. Habert-Ortoli E, Amiranoff B, Loquet I, et al. Molecular cloning of a functional human galanin receptor. Proc Natl Acad Sci USA 1994;91(21):9780-3
56. Jacoby AS, Webb GC, Liu ML, et al. Structural organization of the mouse and human GALR1 galanin receptor genes (Galnr and GALNR) and chromosomal localization of the mouse gene. Genomics 1997;45(3):496-508
57. Waters SM, Krause JE. Distribution of galanin-1, -2 and -3 receptor messenger RNAs in central and peripheral rat tissues. Neuroscience 2000;95(1):265-71
58. Burazin TCD, Larm JA, Ryan MC, Gundlach AL. Galanin-R1 and -R2 receptor mRNA expression during the development of rat brain suggests differential subtype involvement in synaptic transmission and plasticity. Eur J Neurosci 2000;12(8):2901-17
59. Wirz SA, Davis CN, Lu X, et al. Homodimerization and internalization of galanin type 1 receptor in living CHO cells. Neuropeptides 2005;39(6):535-46
60. Xia S, Kjaer S, Zheng K, et al. Visualization of a functionally enhanced GFP-tagged galanin R2 receptor in PC12 cells: constitutive and ligandinduced internalization. Proc Natl Acad Sci USA 2004;101(42):15207-12
61. Wang S, Clemmons A, Strader C, Bayne M. Evidence for hydrophobic interaction between galanin and the GalR1 galanin receptor and GalR1-mediated ligand internalization: fluorescent probing with a fluoresceingalanin. Biochemistry (Mosc) 1998;37(26):9528-35
62. Wang S, Hashemi T, Fried S, et al. Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry (Mosc) 1998;37(19):6711-17
63. Xia S, Dun X-P, Hu P-S, et al. Postendocytotic traffic of the galanin R1 receptor: A lysosomal signal motif on the cytoplasmic terminus. Proc Natl Acad Sci 2008;105(14):5609-13
64. Xia S, Kjaer S, Zheng K, et al. Constitutive and ligand-induced internalization of EGFP-tagged galanin R2 and Rl receptors in PC12 cells. Neuropeptides 2005;39(3):173-8
65. Blackshear A, Yamamoto M, Anderson BJ, et al. Intracerebroventricular administration of galanin or galanin receptor subtype 1 agonist M617 induces c-Fos activation in central amygdala and dorsomedial hypothalamus. Peptides 2007;28(5):1120-4
66. Badie-Mahdavi H, Lu X, Behrens MM, Bartfai T. Role of galanin receptor 1 and galanin receptor 2 activation in synaptic plasticity associated with 3¢,5¢-cyclic AMP response element-binding protein phosphorylation in the dentate gyrus: Studies with a galanin receptor 2 agonist and galanin receptor 1 knockout mice. Neuroscience 2005;133(2):591-604
67. Kinney JW, Sanchez-Alavez M, Barr AM, et al. Impairment of memory consolidation by galanin correlates with in vivo inhibition of both LTP and CREB phosphorylation. Neurobiol Learn Mem 2009;92(3):429-38
68. Howard AD, Tan C, Shiao LL, et al. Molecular cloning and characterization of a new receptor for galanin. FEBS Lett 1997;405(3):285-90
69. Smith KE, Forray C, Walker MW, et al. Expression cloning of a rat hypothalamic galanin receptor coupled to phosphoinositide turnover. J Biol Chem 1997;272(39):24612-16
70. Wang S, Hashemi T, He C, et al. Molecular cloning and pharmacological characterization of a new galanin receptor subtype. Mol Pharmacol 1997;52(3):337-43
71. Kolakowski LF, O'Neill GP, Howard AD, et al. Molecular characterization and expression of cloned human galanin receptors GALR2 and GALR3. J Neurochem 1998;71(6):2239-51
72. Fathi Z, Battaglino PM, Iben LG, et al. Molecular characterization, pharmacological properties and chromosomal localization of the human GALR2 galanin receptor. Brain Res Mol Brain Res 1998;58(1-2):156-69
73. Elliott-Hunt CR, Pope RJP, Vanderplank P, Wynick D. Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage. J Neurochem 2007;100(3):780-9
74. Ding X, MacTavish D, Kar S, Jhamandas JH. Galanin attenuates betaamyloid (Abeta) toxicity in rat cholinergic basal forebrain neurons. Neurobiol Dis 2006;21(2):413-20
75. Hobson S-A, Vanderplank PA, Pope RJP, et al. Galanin stimulates neurite outgrowth from sensory neurons by inhibition of Cdc42 and Rho GTPases and activation of cofilin. J Neurochem 2013;127(2):199-208
76. Wittau N, Grosse R, Kalkbrenner F. The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to Gq, Gi and G12 proteins. Oncogene 2000.19(37):4199-209. Available from: http://www.nature.com/onc/journal/v19/n37/full/1203777a.html [Last accessed 11 April 2015]
77. Wang S, He C, Hashemi T, Bayne M. Cloning and Expressional Characterization of a Novel Galanin Receptor Identification of different pharmacophores within galanin for the three galanin receptor subtypes. J Biol Chem 1997;272(51):31949-52
78. Mennicken F, Hoffert C, Pelletier M, et al. Restricted distribution of galanin receptor 3 (GalR3) mRNA in the adult rat central nervous system. J Chem Neuroanat 2002;24(4):257-68
79. Lerner JT, Sankar R, Mazarati AM. Galanin and epilepsy. Cell Mol Life Sci 2008;65(12):1864-71
80. Lerner JT, Sankar R, Mazarati AM. Galanin and epilepsy. In: Hökfelt T, editor. Galanin [Internet]. Springer Basel; 2010. p. 183-94. Available from: http://link.springer.com/chapter/10.1007/978-3-0346-0228-0-13 [Last accessed 15 April 2015]
81. Zini S, Roisin M-P, Langel U, et al. Galanin reduces release of endogeneous excitatory amino acids in the rat hippocampus. Eur J Pharmacol Mol Pharmacol 1993;245(1):1-7
82. Guipponi M, Chentouf A, Webling KEB, et al. Galanin pathogenic mutations in temporal lobe epilepsy. Hum Mol Genet 2015;24(11):3082-91
83. Wilson DN, Chung H, Elliott RC, et al. Microarray analysis of postictal transcriptional regulation of neuropeptides. J Mol Neurosci 2005;25(3):285-98
84. Fetissov SO, Jacoby AS, Brumovsky PR, et al. Altered hippocampal expression of neuropeptides in seizure-prone GALR1 knockout mice. Epilepsia 2003;44(8):1022-33
85. McColl CD, Jacoby AS, Shine J, et al. Galanin receptor-1 knockout mice exhibit spontaneous epilepsy, abnormal EEGs and altered inhibition in the hippocampus. Neuropharmacology 2006;50(2):209-18
86. Jacoby AS, Hort YJ, Constantinescu G, et al. Critical role for GALR1 galanin receptor in galanin regulation of neuroendocrine function and seizure activity. Brain Res Mol Brain Res 2002;107(2):195-200
87. Mazarati A, Lu X, Shinmei S, et al. Patterns of seizures, hippocampal injury and neurogenesis in three models of status epilepticus in galanin receptor type 1 (GalR1) knockout mice. Neuroscience 2004;128(2):431-41
88. Mazarati A, Lu X, Kilk K, et al. Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus. Eur J Neurosci 2004;19(12):3235-44
89. Gottsch ML, Zeng H, Hohmann JG, et al. Phenotypic analysis of mice deficient in the type 2 galanin receptor (GALR2). Mol Cell Biol 2005;25(11):4804-11
90. Heninger GR, Delgado PL, Charney DS. The revised monoamine theory of depression: a modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. Pharmacopsychiatry 1996;29(1):2-11
91. Weiss JM, Goodman PA, Losito BG, et al. Behavioral depression produced by an uncontrollable stressor: Relationship to norepinephrine, dopamine, and serotonin levels in various regions of rat brain. Brain Res Rev 1981;3(2):167-205
92. Kuteeva E, Wardi T, Hökfelt T, Ogren SO. Galanin enhances and a galanin antagonist attenuates depressionlike behaviour in the rat. Eur Neuropsychopharmacol 2007;17(1):64-9
93. Weiss JM, Bonsall RW, Demetrikopoulos MK, et al. Galanin: a significant role in depression? Ann N Y Acad Sci 1998;863:364-82
94. Kuteeva E, Hökfelt T, Ogren SO. Behavioural characterisation of young adult transgenic mice overexpressing galanin under the PDGF-B promoter. Regul Pept 2005;125(1-3):67-78
95. Xu ZQ, Shi TJ, Hökfelt T. Galanin/GMAP- and NPY-like immunoreactivities in locus coeruleus and noradrenergic nerve terminals in the hippocampal formation and cortex with notes on the galanin-R1 and -R2 receptors. J Comp Neurol 1998;392(2):227-51
96. Xu ZQ, Zhang X, Pieribone VA, et al. Galanin-5-hydroxytryptamine interactions: electrophysiological, immunohistochemical and in situ hybridization studies on rat dorsal raphe neurons with a note on galanin R1 and R2 receptors. Neuroscience 1998;87(1):79-94
97. Misane I, Razani H, Wang FH, et al. Intraventricular galanin modulates a 5-HT1A receptor-mediated behavioural response in the rat. Eur J Neurosci 1998;10(4):1230-40
98. Fuxe K, von Euler G, Agnati LF, Ogren SO. Galanin selectively modulates 5-hydroxytryptamine 1A receptors in the rat ventral limbic cortex. Neurosci Lett 1988;85(1):163-7
99. Razani H, Diaz-Cabiale Z, Fuxe K, Ogren SO. Intraventricular galanin produces a time-dependent modulation of 5-HT1A receptors in the dorsal raphe of the rat. Neuroreport 2000;11(18):3943-8
100. Davidson S, Lear M, Shanley L, et al. Differential activity by polymorphic variants of a remote enhancer that supports galanin expression in the hypothalamus and amygdala: implications for obesity, depression and alcoholism. Neuropsychopharmacology 2011;36(11):2211-21
101. Kuteeva E, Wardi T, Lundström L, et al. Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/stress-related genes at the cell body level. Neuropsychopharmacology 2008;33(11):2573-85
102. Barr AM, Kinney JW, Hill MN, et al. A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests. Neurosci Lett 2006;405(1-2):111-15
103. Lu X, Sharkey L, Bartfai T. The brain galanin receptors: targets for novel antidepressant drugs. CNS Neurol Disord Drug Targets 2007;6(3):183-92
104. Lu X, Ross B, Sanchez-Alavez M, et al. Phenotypic analysis of GalR2 knockout mice in anxiety and depression-related behavioral tests. Neuropeptides 2008;42(4):387-97
105. Hyman BT. Molecular and anatomical studies in Alzheimer's disease. Neurol Barc Spain 2001;16(3):100-4
106. Pearson RC, Esiri MM, Hiorns RW, et al. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci USA 1985;82(13):4531-4
107. Ikonomovic MD, Mufson EJ, Wuu J, et al. Reduction of choline acetyltransferase activity in primary visual cortex in mild to moderate Alzheimer's disease. Arch Neurol 2005;62(3):425-30
108. Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 1989;287(3):373-92
109. Chan-Palay V. Galanin hyperinnervates surviving neurons of the human basal nucleus of Meynert in dementias of Alzheimer's and Parkinson's disease: a hypothesis for the role of galanin in accentuating cholinergic dysfunction in dementia. J Comp Neurol 1988;273(4):543-57
110. Mufson EJ, Cochran E, Benzing W, Kordower JH. Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the stria terminalis in aging, Alzheimer's disease and Down's syndrome. Dement Basel Switz 1993;4(5):237-50
111. Miller MA, Kolb PE, Leverenz JB, et al. Preservation of noradrenergic neurons in the locus ceruleus that coexpress galanin mRNA in Alzheimer's disease. J Neurochem 1999;73(5):2028-36
112. Crawley JN. Galanin impairs cognitive abilities in rodents: relevance to Alzheimer's Disease. Cell Mol Life Sci CMLS 2008;65(12):1836-41
113. Deecher DC, Mash DC, Staley JK, Mufson EJ. Characterization and localization of galanin receptors in human entorhinal cortex. Regul Pept 1998;73(3):149-59
114. Pérez S, Basile M, Mash DC, Mufson EJ. Galanin receptor overexpression within the amygdala in early Alzheimer's disease: an in vitro autoradiographic analysis. J Chem Neuroanat 2002;24(2):109-16
115. Rodríguez-Puertas R, Nilsson S, Pascual J, et al. 125I-galanin binding sites in Alzheimer's disease: increases in hippocampal subfields and a decrease in the caudate nucleus. J Neurochem 1997;68(3):1106-13
116. Sundström E, Archer T, Melander T, Hökfelt T. Galanin impairs acquisition but not retrieval of spatial memory in rats studied in the Morris swim maze. Neurosci Lett 1988;88(3):331-5
117. Counts SE, Pérez SE, Ginsberg SD, Mufson EJ. Neuroprotective role for galanin in Alzheimer's disease. EXS 2010;102:143-62
118. McDonald MP, Crawley JN. Galanin receptor antagonist M40 blocks galanininduced choice accuracy deficits on a delayed-nonmatching-to-position task. Behav Neurosci 1996;110(5):1025-32
119. Fisone G, Wu CF, Consolo S, et al. Galanin inhibits acetylcholine release in the ventral hippocampus of the rat: histochemical, autoradiographic, in vivo, and in vitro studies. Proc Natl Acad Sci USA 1987;84(20):7339-43
120. Wilcock GK, Esiri MM, Bowen DM, Smith CC. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J Neurol Sci 1982;57(2-3):407-17
121. Counts SE, Perez SE, Mufson EJ. Galanin in Alzheimer's disease: neuroinhibitory or neuroprotective? Cell Mol Life Sci 2008;65(12):1842-53
122. Beal MF, MacGarvey U, Swartz KJ. Galanin immunoreactivity is increased in the nucleus basalis of meynert in Alzheimer's disease. Ann Neurol 1990;28(2):157-61
123. Mufson EJ, Deecher DC, Basile M, et al. Galanin receptor plasticity within the nucleus basalis in early and late Alzheimer's disease: an in vitro autoradiographic analysis. Neuropharmacology 2000;39(8):1404-12
124. Counts SE, Chen E-Y, Che S, et al. Galanin fiber hypertrophy within the cholinergic nucleus basalis during the progression of Alzheimer's disease. Dement Geriatr Cogn Disord 2006;21(4):205-14
125. Counts SE, He B, Che S, et al. Galanin Hyperinnervation Upregulates Choline Acetyltransferase Expression in Cholinergic Basal Forebrain Neurons in Alzheimer's Disease. Neurodegener Dis 2008;5(3-4):228-31
126. Counts SE, He B, Che S, et al. Galanin Fiber Hyperinnervation Preserves Neuroprotective Gene Expression in Cholinergic Basal Forebrain Neurons in Alzheimer's Disease. J Alzheimers Dis 2009;18(4):885-96
127. Li L, Yu L, Kong Q. Exogenous galanin attenuates spatial memory impairment and decreases hippocampal β-amyloid levels in rat model of Alzheimer's disease. Int J Neurosci 2013;123(11):759-65
128. Elliott-Hunt CR, Marsh B, Bacon A, et al. Galanin acts as a neuroprotective factor to the hippocampus. Proc Natl Acad Sci USA 2004;101(14):5105-10
129. Min C, Mierzwa R, Truumees I, et al. A New fungal metabolite, Sch 202596, with inhibitory activity in the galanin receptor GALR1 Assay. Tetrahedron Lett 1997;38(35):6111-14
130. Scott MK, Ross TM, Lee DHS, et al. 2,3-Dihydro-dithiin and -dithiepine-1,1,4,4-tetroxides: small molecule nonpeptide antagonists of the human galanin hGAL-1 receptor. Bioorg Med Chem 2000;8(6):1383-91
131. Ceide SC, Trembleau L, Haberhauer G, et al. Synthesis of galmic: A nonpeptide galanin receptor agonist. Proc Natl Acad Sci USA 2004;101(48):16727-32
132. Saar K, Mazarati AM, Mahlapuu R, et al. Anticonvulsant activity of a nonpeptide galanin receptor agonist. Proc Natl Acad Sci USA 2002;99(10):7136-41
133. Bartfai T, Lu X, Badie-Mahdavi H, et al. Galmic, a nonpeptide galanin receptor agonist, affects behaviors in seizure, pain, and forced-swim tests. Proc Natl Acad Sci USA 2004;101(28):10470-5
134. Lu X, Lundström L, Langel U, Bartfai T. Galanin receptor ligands. Neuropeptides 2005;39(3):143-6
135. Konkel MJ, Packiarajan M, Chen H, et al. Amino substituted analogs of 1-phenyl-3-phenylimino-2-indolones with potent galanin Gal3 receptor binding affinity and improved solubility. Bioorg Med Chem Lett 2006;16(15):3950-4
136. Swanson CJ, Blackburn TP, Zhang X, et al. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci USA 2005;102(48):17489-94
137. Lu X, Roberts E, Xia F, et al. GalR2-positive allosteric modulator exhibits anticonvulsant effects in animal models. Proc Natl Acad Sci USA 2010;107(34):15229-34
138. Liu HX, Brumovsky P, Schmidt R, et al. Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: selective actions via GalR1 and GalR2 receptors. Proc Natl Acad Sci USA 2001;98(17):9960-4
139. Lu X, Lundström L, Bartfai T. Galanin (2-11) binds to GalR3 in transfected cell lines: limitations for pharmacological definition of receptor subtypes. Neuropeptides 2005;39(3):165-7
140. Bartfai T, Bedecs K, Land T, et al. M-15: high-affinity chimeric peptide that blocks the neuronal actions of galanin in the hippocampus, locus coeruleus, and spinal cord. Proc Natl Acad Sci USA 1991;88(23):10961-5
141. Crawley JN, Robinson JK, Langel U, Bartfai T. Galanin receptor antagonists M40 and C7 block galanin-induced feeding. Brain Res 1993;600(2):268-72
142. Ögren SO, Hökfelt T, Kask K, et al. Evidence for a role of the neuropeptide galanin in spatial learning. Neuroscience 1992;51(1):1-5
143. Lundström L, Sollenberg U, Brewer A, et al. A galanin receptor subtype 1 specific agonist. Int J Pept Res Ther 2005;11(1):17-27
144. Sollenberg UE, Lundström L, Bartfai T, Langel Ü. M871-a novel peptide antagonist selectively recognizing the galanin receptor type 2. Int J Pept Res Ther 2006;12(2):115-19
145. Sollenberg UE, Runesson J, Sillard R, Langel Ü. Binding of chimeric peptides M617 and M871 to galanin receptor type 3 reveals characteristics of galanin receptor-ligand interaction. Int J Pept Res Ther 2010;16(1):17-22
146. Saar I, Runesson J, McNamara I, et al. Novel galanin receptor subtype specific ligands in feeding regulation. Neurochem Int 2011;58(6):714-20
147. Bulaj G, Green BR, Lee H-K, et al. Design, synthesis, and characterization of high-affinity, systemically-active galanin analogues with potent anticonvulsant activities. J Med Chem 2008;51(24):8038-47
148. Saar I, Lahe J, Langel K, et al. Novel systemically active galanin receptor 2 ligands in depression-like behavior. J Neurochem 2013;127(1):114-23
149. Hulse RP, Donaldson LF, Wynick D. Peripheral galanin receptor 2 as a target for the modulation of pain. Pain Res Treat 2012;2012:e545386
150. Swanson CJ, Blackburn TP, Zhang X, et al. Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299. Proc Natl Acad Sci USA 2005;102(48):17489-94
151. Borowsky B, Walker MW, Huang L-Y, et al. Cloning and characterization of the human galanin GALR2 receptor. Peptides 1998;19(10):1771-81
152. Smith KE, Walker MW, Artymyshyn R, et al. Cloned human and rat galanin GALR3 receptors. Pharmacology and activation of G-protein inwardly rectifying K+ channels. J Biol Chem 1998;273(36):23321-6